HUTCHMED Highlights Positive Phase III SACHI Results in The Lancet for NSCLC Combination Therapy
HCM sits 32% above its 52-week low of $11.505.
Summary
HUTCHMED announced the publication of positive Phase III SACHI trial results in The Lancet, validating the efficacy of its savolitinib and osimertinib combination for advanced NSCLC.
Key Events · Product Development and Regulatory · HCM
-
Phase III SACHI Results Published in The Lancet
The full results from the SACHI Phase III trial, evaluating the savolitinib and osimertinib combination for advanced NSCLC, were published in the prestigious medical journal, The Lancet.
-
Significant Efficacy Demonstrated
The trial met its primary endpoint, showing a median progression-free survival of 8.2 months for the combination therapy compared to 4.5 months for chemotherapy (HR 0.34; p<0.0001). The objective response rate was 58% versus 34%.
-
Reinforces China Approval and Global Development
The combination was already approved in China in June 2025 based on interim SACHI data. This publication provides robust scientific backing, supporting ongoing global development efforts like the SAFFRON trial for potential US FDA registration.
-
Tolerable Safety Profile
The safety profile of the savolitinib and osimertinib combination was found to be tolerable, with no new safety signals observed during the trial.
Analysis · HCM · Life Sciences
The publication of the full Phase III SACHI trial results in The Lancet provides strong scientific validation for HUTCHMED's savolitinib and osimertinib combination therapy. The study demonstrated significant improvements in progression-free survival and objective response rates for patients with EGFR-mutated NSCLC with MET amplification, a challenging patient population. While the combination is already approved in China, this publication reinforces the drug's efficacy and safety profile, bolstering its global development prospects, including the ongoing SAFFRON trial for potential US FDA registration.
At the time of this filing, HCM was trading at $15.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $11.51 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.